AOAya F. Ozaki

Aya F. Ozaki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aya F. Ozaki has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Machine learning approaches to predict early cardiac immune-related adverse events in patients receiving immune checkpoint inhibitors

    by Michael Sayer, Peter D. Chang, Hirofumi Hamano, Reina Yamamoto, Misako Nagasaka, Ali A. Naqvi, Pranav M. Patel, Yoshito Zamami, Aya F. Ozaki

    Purpose: Immune checkpoint inhibitor (ICI)–induced cardiac immune-related adverse events (cardiac irAEs) are rare yet serious complications. Clinical assessment tools to identify at-risk patients would allow for more effective prevention strategies, thus improving clinical outcomes. We constructed various machine learning (ML) models to predict these events among patients receiving ICI therapy. Methods: A cohort of patients receiving ICI therapy from 2010 to 2023 was identified from the TriNetX database. Cardiac irAEs were defined as the occurrence of relevant diagnosis codes within 90 days of ICI initiation, with corresponding hospital visits. We created ML models to predict these events, including elastic net logistic regression and multiple tree-based approaches (gradient boosted trees and random forest). We evaluated model performance with different performance measures and utilized assigned risk scores to stratify risk of cardiac irAEs into low, medium, and high-risk tiers. Results: We identified 61,117 patients receiving ICI therapy, with nearly 2% of patients experiencing cardiac irAEs. Model performance on testing data was comparable with all approaches (AUC = 0.71–0.72, balanced accuracy = 65–66%). Each model emphasized distinct features to make classifications, as observed with feature importance and SHAP values. Comparing cardiac irAE rates among assigned risk strata, patients identified as high risk were significantly more likely to experience cardiac irAEs compared to lower tiers. Conclusion: Our preliminary exploration of ML methods demonstrated the potential for risk assessment tools to predict rare cardiac irAEs in patients receiving ICI therapy. Follow-up studies can implement time series approaches to harness longitudinal data that incorporates real-time labs, new diagnoses, and new therapy, to refine predictions further.

  • Open Access

    Prescription patterns of sacubitril/valsartan among patients with hypertension in Japan

    by Aya F. Ozaki, Hisanaga Nomura, Tomohiro Terada, Eri T. Kato, Ali A. Naqvi, Julie T. Nguyen, Yuki Kunitsu

    Background: Sacubitril/valsartan (S/V) is an established therapy for heart failure that has been recently approved for hypertension in Japan. However, evidence regarding its use in combination with other antihypertensive agents in real-world practice is limited. Objective: To describe real-world prescribing patterns of S/V among patients with hypertension in Japan. Methods: A retrospective cohort study using a nationwide Japanese electronic health record database (August 2020 to October 2023) identified adults with hypertension (ICD-10: I10–I15) who were newly prescribed S/V. Patients with heart failure were excluded. Concomitant antihypertensive medications, S/V dosing, and discontinuation patterns were assessed over 90 days following initiation. Results: Of the 9,486 patients (median age 79 years; 50.6% men), 63.6% received S/V with a calcium channel blocker (CCB), 22.5% as monotherapy, and 11.8% as triple therapy with CCB and thiazide. At day 90, 55.5% of patients received S/V plus a CCB, and 26.0% were on S/V monotherapy. The S/V discontinuation rate reached 11.8% by day 90. Approximately half of those on triple therapy discontinued the thiazide diuretic within 30 days. Conclusions: In Japanese patients with hypertension, S/V is most commonly used in combination with a CCB, although a notable proportion receive it as monotherapy. These findings highlight the need for further studies to evaluate the safety, efficacy, and cost-effectiveness of S/V-based combination regimens.

  • Open Access

    Correction: Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement

    by Susan Dent, Michelle B. Nadler, Anne Blaes, Ahamed Iqbal, Hannah Naa Gogwe Ayettey, Jose Alvarez-Cardona, Alexandre Chan, Eng-Siew Koh, Raul Cordoba Mascunano, Mridula George, et al.

  • Open Access

    Correction: Prevention and management of cardiovascular disease in adults with cancer: an International Cardio‑Oncology Society (IC‑OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement

    by Susan Dent, Michelle B. Nadler, Anne Blaes, Ahamed Iqbal, Hannah Naa Gogwe Ayettey, Jose Alvarez-Cardona, Alexandre Chan, Eng-Siew Koh, Raul Cordoba Mascunano, Mridula George, et al.

  • Open Access

    Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement

    by Susan Dent, Michelle B Nadler, Anne Blaes, Ahamed Iqbal, Hannah Naa Gogwe Ayettey, Jose Alvarez-Cardona, Alexandre Chan, Eng-Siew Koh, Raul Cordoba Mascunano, Mridula George, et al.

    Cardiovascular (CV) toxicity is prevalent in cancer survivors due to shared risk factors, direct CV injury from cancer therapy (CT), and development/exacer


  • Open Access

    Prevention and management of cardiovascular disease in adults with cancer: an International Cardio-Oncology Society (IC-OS) and Multinational Association of Supportive Care in Cancer (MASCC) clinical practice statement

    by Susan Dent, Michelle B. Nadler, Anne Blaes, Ahamed Iqbal, Hannah Naa Gogwe Ayettey, Jose Alvarez-Cardona, Alexandre Chan, Eng-Siew Koh, Raul Cordoba Mascunano, Mridula George, et al.

    Purpose Cardiovascular (CV) toxicity is prevalent in cancer survivors due to shared risk factors, direct CV injury from cancer therapy (CT), and development/exacerbation of CV risk factors during treatment. Succinct guidance on the minimum standard of CV care required of cancer care providers (CCPs) can improve outcomes for survivors. This clinical practice statement (CPS) is aimed at CCPs focused on identification, prevention, and management of CVD in individuals with cancer. Methods The International Cardio-Oncology Society and Multinational Association of Supportive Care in Cancer identified members with expertise across oncology, cardiology, and cancer survivorship. Key questions/areas of practice recommendations related to CV risk and CVD were identified across the cancer trajectory.Working groups performed targeted literature reviews and consensus was reached for all recommendations. Results 5 over-arching clinical practice recommendations for CCPs were identified: (1) perform a CV risk assessment prior to starting CT (2) identify and facilitate CV-related care during CT; (3) ensure measures are taken to mitigate the risk of cancer therapy related CV toxicity (CTR-CVT) prior to and during CT; (4) monitor CV status and risk factors during therapy and refer to the appropriate health care provider if CV risk factors are uncontrolled or new signs/symptoms develop; and (5) re-assess CV risk following completion of CT (periodically for those with advanced disease on life long treatment) and develop a CV surveillance plan. Conclusions CCPs play a pivotal role in identifying and addressing CTR-CVT. This CPS provides specific, succinct, and actionable behaviours that can be readily implemented in cancer care globally. Graphical Abstract The alternative text for this image may have been generated using AI.

  • Open Access

    Balancing the Risk of Cardiotoxicity Outcomes in Treatment Selection for Multiple Myeloma: A Retrospective Multicenter Evaluation of Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (KRd)

    by Benjamin J. Lee, Michael Sayer, Ali A. Naqvi, Karen T. Mai, Pranav M. Patel, Lisa X. Lee, Aya F. Ozaki

    Introduction: Carfilzomib use has been extensively associated with cardiovascular toxicity; the risk with ixazomib, a novel oral proteasome inhibitor, is underreported and no large comparative analysis is available.Methods: We conducted a retrospective cohort study utilizing the TriNetX platform to compare toxicity outcomes among multiple myeloma patients who received lenalidomide, dexamethasone, and ixazomib (IRd) or carfilzomib (KRd).Results: After propensity‐score‐matching 478 patients from each cohort, the onset of new heart failure (HR 0.25; p < 0.001) and arrhythmias (HR 0.57; p = 0.014) at 6 months were significantly lower with IRd while overall survival at 3 years was similar (p = 0.50).Conclusion: IRd is associated with a significantly lower risk of cardiac toxicities compared to KRd.


  • Open Access

    Time dependent predictors of cardiac inflammatory adverse events in cancer patients receiving immune checkpoint inhibitors

    by Michael Sayer, Hirofumi Hamano, Misako Nagasaka, Benjamin J. Lee, Jean Doh, Pranav M. Patel, Yoshito Zamami, Aya F. Ozaki

    Background: Cardio-inflammatory immune related adverse events (irAEs) while receiving immune checkpoint inhibitor (ICI) therapy are particularly consequential due to their associations with poorer treatment outcomes. Evaluation of predictive factors of these serious irAEs with a time dependent approach allows better understanding of patients most at risk. Objective: To identify different elements of patient data that are significant predictors of early and late-onset or delayed cardio-inflammatory irAEs through various predictive modeling strategies. Methods: A cohort of patients receiving ICI therapy from January 1, 2010 to May 1, 2022 was identified from TriNetX meeting inclusion/exclusion criteria. Patient data collected included occurrence of early and later cardio-inflammatory irAEs, patient survival time, patient demographic information, ICI therapies, comorbidities, and medication histories. Predictive and statistical modeling approaches identified unique risk factors for early and later developing cardio-inflammatory irAEs. Results: A cohort of 66,068 patients on ICI therapy were identified in the TriNetX platform; 193 (0.30%) experienced early cardio-inflammatory irAEs and 175 (0.26%) experienced later cardio-inflammatory irAEs. Significant predictors for early irAEs included: anti-PD-1 therapy at index, combination ICI therapy at index, and history of peripheral vascular disease. Significant predictors for later irAEs included: a history of myocarditis and/or pericarditis, cerebrovascular disease, and history of non-steroidal anti-inflammatory medication use. Conclusions: Cardio-inflammatory irAEs can be divided into clinically meaningful categories of early and late based on time since initiation of ICI therapy. Considering distinct risk factors for early-onset and late-onset events may allow for more effective patient monitoring and risk assessment.


  • Open Access

    Incidence and survival outcomes of myocarditis and pericardial diseases associated with immune checkpoint inhibitor therapy

    by Aya F. Ozaki, Michael Sayer, Hirofumi Hamano, Misako Nagasaka, Benjamin J. Lee, Jean Doh, Ali Naqvi, Nareh Nowrouzi, Yoshito Zamami, Pranav M. Patel

    Introduction: Immune checkpoint inhibitor(ICI) induced cardiac immune related adverse events are challenging to study; Leveraging large data bases like TriNetX global health network may provide needed insights. Methods: We performed a retrospective cohort study including patients diagnosed neoplasm and 18 and older when receiving ICI therapy from 1/1/2011 to 12/31/2022. Queried ICD 9/10 codes identified patients experiencing myocarditis, pericarditis, pericardial effusion, and cardiac tamponade within 1 year of ICI initiation. Survival analyses compared one-year overall survival (OS) of patients experiencing cardiac irAEs against propensity score matched populations not experiencing them. Results: In 88,928 identified ICI patients, the incidence of myocarditis(0.48%), pericarditis(0.22%), and cardiac tamponade(0.47%) were less than 1% while pericardial effusion occurred in 4.71% of patients. Hazard ratios (HRs) were significantly higher in all cardiac irAE groups: myocarditis (HR:1.26, 95% CI:1.04–1.54, p = 0.02), pericarditis (HR:1.36, 95% CI:1.02–1.82, p = 0.04), pericardial effusion (HR:1.49, 95% CI:1.39–1.59, p < 0.0001), cardiac tamponade (HR:2.15, 95% CI:1.79–2.57, p < 0.0001), and overall pericardial disease (HR:1.46, 95% CI:1.37–1.56, p < 0.0001). There was no significant difference in OS between myocarditis and pericarditis or overall pericardial diseases. Discussion/conclusion: Utilizing a uniquely large cohort of ICI patients, this study further shows the rarity of cardiac inflammatory irAEs and highlights their significant impact on patient survival.